Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CD226: a potent driver of antitumor immunity that needs to be maintained

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1


  1. Weulersse, M. et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell anti-tumor functions and limits the efficacy of cancer immunotherapy. Immunity 53, 824–839. e810 (2020).

    Article  CAS  Google Scholar 

  2. Braun, M. et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity 53, 805–823. e815 (2020).

    Article  CAS  Google Scholar 

  3. Martinet, L. & Smyth, M. J. Balancing natural killer cell activation through paired receptors. Nat. Rev. Immunol. 15, 243–254 (2015).

    Article  CAS  Google Scholar 

  4. Johnston, R. J. et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 26, 923–937 (2014).

    Article  CAS  Google Scholar 

  5. Zhang, Q. et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat. Immunol. 19, 723–732 (2018).

    Article  CAS  Google Scholar 

  6. Blake, S. J. et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6, 446–459 (2016).

    Article  CAS  Google Scholar 

  7. O’Donnell, J. S., Madore, J., Li, X. Y. & Smyth, M. J. Tumor intrinsic and extrinsic immune functions of CD155. Semin. Cancer Biol. 65, 189–196 (2020).

    Article  Google Scholar 

  8. Kucan Brlic, P. et al. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell. Mol. Immunol. 16, 40–52 (2019).

    Article  CAS  Google Scholar 

  9. Li, X. Y. et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J. Clin. Investig. 128, 2613–2625 (2018).

    Article  Google Scholar 

  10. Morimoto, K. et al. Interaction of cancer cells with platelets mediated by Necl-5/poliovirus receptor enhances cancer cell metastasis to the lungs. Oncogene 27, 264–273 (2008).

    Article  CAS  Google Scholar 

Download references


This work was supported by the National Key R&D Program of China (2020YFA0710802) and the Natural Science Foundation of China (reference number 82071768).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jiacheng Bi.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bi, J. CD226: a potent driver of antitumor immunity that needs to be maintained. Cell Mol Immunol 19, 969–970 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links